+Compare
CTMX
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
89.1M

CTMX CytomX Therapeutics Forecast, Technical & Fundamental Analysis

an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for CTMX with price predictions
07:00 PM EST Nov 30, 2023

Momentum Indicator for CTMX turns positive, indicating new upward trend

CTMX saw its Momentum Indicator move above the 0 level on November 07, 2023. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CTMX's RSI Indicator exited the oversold zone, of 47 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CTMX just turned positive on November 03, 2023. Looking at past instances where CTMX's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

CTMX moved above its 50-day moving average on November 14, 2023 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CTMX crossed bullishly above the 50-day moving average on November 20, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CTMX advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .

CTMX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 133 cases where CTMX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTMX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CTMX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.155) is normal, around the industry mean (20.645). P/E Ratio (0.000) is within average values for comparable stocks, (137.274). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (0.997) is also within normal values, averaging (329.009).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTMX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 3%. For the same Industry, the average monthly price growth was 31%, and the average quarterly price growth was 27%. MMIRF experienced the highest price growth at 247%, while BRRGF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 173%. For the same stocks of the Industry, the average monthly volume growth was -7% and the average quarterly volume growth was 52%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 58
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: 25 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

CTMX is expected to report earnings to fall 253.25% to -6 cents per share on February 28

CytomX Therapeutics CTMX Stock Earnings Reports
Q4'23
Est.
$-0.06
Q3'23
Beat
by $0.23
Q2'23
Beat
by $0.17
Q1'23
Beat
by $0.06
Q4'22
Missed
by $0.18
The last earnings report on November 07 showed earnings per share of 3 cents, beating the estimate of -18 cents. With 199.01K shares outstanding, the current market capitalization sits at 89.10M.
A.I. Advisor
published General Information

General Information

an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
151 Oyster Point Boulevard
Phone
+1 650 515-3185
Employees
118
Web
https://www.cytomx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IAMOX2.680.04
+1.52%
Voya MidCap Opportunities Port A
JETMF0.700.01
+1.45%
Global Crossing Airlines Group
OLVAX19.130.27
+1.43%
JPMorgan Large Cap Value A
EGLCX7.860.07
+0.90%
Eagle MLP Strategy C
BQLCX20.800.07
+0.34%
Bright Rock Quality Large Cap Instl

CTMX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CTMX has been loosely correlated with SPRB. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CTMX jumps, then SPRB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CTMX
1D Price
Change %
CTMX100%
+1.44%
SPRB - CTMX
50%
Loosely correlated
+6.43%
ANAB - CTMX
41%
Loosely correlated
+6.08%
CVAC - CTMX
40%
Loosely correlated
+1.85%
ABUS - CTMX
40%
Loosely correlated
-0.98%
ALLO - CTMX
38%
Loosely correlated
+7.23%
More

Groups containing CTMX

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CTMX
1D Price
Change %
CTMX100%
+1.44%
drugs
(undefined stocks)
40%
Loosely correlated
+2.08%
cancer
(undefined stocks)
39%
Loosely correlated
+1.96%
biotechnology
(undefined stocks)
35%
Loosely correlated
+2.01%
biopharmaceuticals
(undefined stocks)
34%
Loosely correlated
+2.04%
therapy
(undefined stocks)
32%
Poorly correlated
+2.22%
More